NASDAQ:AEZS Aeterna Zentaris (AEZS) Stock Price, News & Analysis $5.35 -0.05 (-0.93%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$5.35▼$5.4850-Day Range$4.41▼$10.2552-Week Range$3.96▼$12.36Volume1,669 shsAverage Volume7,479 shsMarket Capitalization$9.58 millionP/E RatioN/ADividend YieldN/APrice Target$60.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrends Get Aeterna Zentaris alerts: Email Address Aeterna Zentaris MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,021.5% Upside$60.00 Price TargetShort InterestHealthy0.18% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.72Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.59 out of 5 stars 3.5 Analyst's Opinion Consensus RatingAeterna Zentaris has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageAeterna Zentaris has received no research coverage in the past 90 days.Read more about Aeterna Zentaris' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.18% of the float of Aeterna Zentaris has been sold short.Short Interest Ratio / Days to CoverAeterna Zentaris has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aeterna Zentaris has recently decreased by 7.02%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAeterna Zentaris does not currently pay a dividend.Dividend GrowthAeterna Zentaris does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AEZS. Previous Next 2.6 News and Social Media Coverage News SentimentAeterna Zentaris has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Aeterna Zentaris this week, compared to 0 articles on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aeterna Zentaris insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.10% of the stock of Aeterna Zentaris is held by insiders.Percentage Held by InstitutionsOnly 0.73% of the stock of Aeterna Zentaris is held by institutions.Read more about Aeterna Zentaris' insider trading history. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Aeterna Zentaris is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aeterna Zentaris is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAeterna Zentaris has a P/B Ratio of 0.36. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Aeterna Zentaris' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad American Hartford Gold GroupDave Ramsey Makes Big Mistake Live On AirDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.GET THE FREE GUIDE About Aeterna Zentaris Stock (NASDAQ:AEZS)Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.Read More AEZS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AEZS Stock News HeadlinesJuly 19, 2024 | finance.yahoo.comChimerix Inc (CXF.BE)July 19, 2024 | americanbankingnews.comAeterna Zentaris (NASDAQ:AEZS) Coverage Initiated at StockNews.comJuly 26, 2024 | American Hartford Gold Group (Ad)Prepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.July 16, 2024 | globenewswire.comAeterna Zentaris Announces Results of Virtual 2024 Meeting of ShareholdersJune 13, 2024 | globenewswire.comAeterna Zentaris Announces Last Patient Last Visit in Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone DeficiencyJune 7, 2024 | prnewswire.comShareholder Alert: Ademi LLP investigates whether Aeterna Zentaris Inc.'s transaction with Ceapro was Fair to ShareholdersJune 3, 2024 | globenewswire.comAeterna Zentaris and Ceapro Complete Merger TransactionMay 29, 2024 | globenewswire.comAeterna Zentaris Provides Update on Timing for Annual Meeting of Shareholders and Due Bill Redemption DateJuly 26, 2024 | American Hartford Gold Group (Ad)Prepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.May 27, 2024 | finanznachrichten.deAeterna Zentaris Inc: Aeterna Zentaris Announces Details Regarding Transaction with CeaproMay 17, 2024 | finance.yahoo.comAeterna Zentaris Announces Details Regarding Transaction with CeaproMay 17, 2024 | globenewswire.comAeterna Zentaris Announces Details Regarding Transaction with CeaproMay 15, 2024 | finanznachrichten.deAeterna Zentaris Inc: Aeterna Zentaris Reports First Quarter 2024 Financial ResultsMay 14, 2024 | washingtonpost.comAeterna Zentaris: Q1 Earnings SnapshotMay 14, 2024 | globenewswire.comAeterna Zentaris Reports First Quarter 2024 Financial ResultsMay 1, 2024 | globenewswire.comAeterna Zentaris Announces Effective Date of Share ConsolidationApril 28, 2024 | finance.yahoo.com12 ChatGPT Penny Stock Picks Right NowApril 2, 2024 | theglobeandmail.comAuxly Cannabis Group: Top 10 Undervalued Healthcare Sector Stocks on TSX (XLY)See More Headlines Receive AEZS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aeterna Zentaris and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today7/26/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AEZS CUSIPN/A CIK1113423 Webwww.zentaris.com Phone(418) 652-8525Fax418-948-9191Employees11Year FoundedN/APrice Target and Rating Average Stock Price Target$60.00 High Stock Price Target$60.00 Low Stock Price Target$60.00 Potential Upside/Downside+1,021.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($14.86) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-16,550,000.00 Net Margins-760.32% Pretax Margin-760.28% Return on Equity-83.45% Return on Assets-45.76% Debt Debt-to-Equity RatioN/A Current Ratio5.94 Quick Ratio5.93 Sales & Book Value Annual Sales$4.50 million Price / Sales2.13 Cash FlowN/A Price / Cash FlowN/A Book Value$14.99 per share Price / Book0.36Miscellaneous Outstanding Shares1,790,000Free Float1,791,000Market Cap$9.58 million OptionableNo Data Beta1.55 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.Get This Free Report Key ExecutivesDr. Klaus Paulini Ph.D.President, CEO & Executive DirectorMr. Giuliano La FrattaSenior VP of Finance & CFODr. Michael Teifel Ph.D.Senior VP of Non-Clinical Development & Chief Scientific OfficerDr. Nicola Ammer M.D.Chief Medical Officer & Senior VP of Clinical DevelopmentDr. Matthias GerlachSenior Vice President Manufacturing & Supply ChainKey CompetitorsCorrevio PharmaNASDAQ:CORVAadi BioscienceNASDAQ:AADIMIRA PharmaceuticalsNASDAQ:MIRAXilio TherapeuticsNASDAQ:XLOAcurx PharmaceuticalsNASDAQ:ACXPView All Competitors AEZS Stock Analysis - Frequently Asked Questions How have AEZS shares performed this year? Aeterna Zentaris' stock was trading at $7.44 on January 1st, 2024. Since then, AEZS shares have decreased by 28.1% and is now trading at $5.35. View the best growth stocks for 2024 here. How were Aeterna Zentaris' earnings last quarter? Aeterna Zentaris Inc. (NASDAQ:AEZS) released its quarterly earnings data on Tuesday, May, 14th. The biopharmaceutical company reported ($4.74) EPS for the quarter. Aeterna Zentaris had a negative trailing twelve-month return on equity of 83.45% and a negative net margin of 760.32%. When did Aeterna Zentaris' stock split? Aeterna Zentaris's stock reverse split before market open on Friday, May 3rd 2024. The 1-4 reverse split was announced on Friday, May 3rd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 3rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split. Who are Aeterna Zentaris' major shareholders? Top institutional investors of Aeterna Zentaris include Concourse Financial Group Securities Inc.. How do I buy shares of Aeterna Zentaris? Shares of AEZS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Aeterna Zentaris own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aeterna Zentaris investors own include Zosano Pharma (ZSAN), Pennsylvania Real Estate Investment Trust (PEI), CBL & Associates Properties (CBL), CNBX Pharmaceuticals (CNBX), Matinas BioPharma (MTNB) and ADMA Biologics (ADMA). This page (NASDAQ:AEZS) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredWhy is NVDA stumbling?July is historically the best month of the year for U.S. stocks. So why are everyone’s favorite tech stocks...Chaikin Analytics | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aeterna Zentaris Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aeterna Zentaris With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
